Myelodysplastic Syndrome Market Research Report present a detailed analysis of the market listing Myelodysplastic Syndrome Epidemiology, Drug therapies and pipeline for study period from 2018-2030.

Myelodysplastic Syndrome Market Size & Share | Myelodysplastic Syndrome Market Research Report, Market Analysis, Market Growth, trends and Forecast

DelveInsight&rsquo;s &lsquo;Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast&ndash; 2030&rsquo; report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), And Japan.
The Myelodysplastic Syndrome market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Myelodysplastic Syndrome market size from 2018 to 2030. The report also covers current Myelodysplastic Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
<h2>Geography Covered</h2>
<ul>
<li>The United States</li>
<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
<li>Japan</li>
</ul>
Study Period: 2018&ndash;2030
<h3>Myelodysplastic Syndrome Disease Understanding and Treatment Algorithm</h3>
The&nbsp;DelveInsight&rsquo;s&nbsp;Myelodysplastic Syndrome market report gives a thorough understanding of the Myelodysplastic Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
<h3>Myelodysplastic Syndrome Diagnosis</h3>
This segment of the report covers the detailed diagnostic methods or tests for Myelodysplastic Syndrome.
<h3>Myelodysplastic Syndrome Treatment</h3>
It covers the details of conventional and current medical therapies available in the Myelodysplastic Syndrome market for the treatment of the condition. It also provides Myelodysplastic Syndrome treatment algorithms and guidelines in the United States, Europe, and Japan.
<h2>Myelodysplastic Syndrome Epidemiology&nbsp;</h2>
The Myelodysplastic Syndrome epidemiology&nbsp;section&nbsp;provides insights about the historical and current Myelodysplastic Syndrome patient pool and forecasted trends for&nbsp;individual&nbsp;seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the&nbsp;Myelodysplastic Syndrome market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Myelodysplastic Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Myelodysplastic Syndrome Epidemiology
The epidemiology segment also provides the Myelodysplastic Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
<h2>Myelodysplastic Syndrome Drug Chapters</h2>
The drug chapter segment of the Myelodysplastic Syndrome report encloses the detailed analysis of Myelodysplastic Syndrome marketed drugs and late-stage (Phase-III and Phase-II)&nbsp;Myelodysplastic Syndrome pipeline drugs. It also helps to understand the Myelodysplastic Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
<h3>Myelodysplastic Syndrome Marketed Drugs</h3>
The report provides the details of the marketed products/off-label treatments available for Myelodysplastic Syndrome treatment.
<h3>Myelodysplastic Syndrome Emerging Drugs</h3>
The report provides the details of the emerging therapies under the late and mid-stage of development for Myelodysplastic Syndrome treatment.
<h2>Myelodysplastic Syndrome Market Outlook</h2>
The Myelodysplastic Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Myelodysplastic Syndrome market trends by analyzing the impact of current&nbsp;Myelodysplastic Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Myelodysplastic Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Myelodysplastic Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Myelodysplastic Syndrome market in 7MM is expected to witness a major change in the study period 2018 to 2030.
Key Findings
This section includes a glimpse of the Myelodysplastic Syndrome market in 7MM.
The United States Market Outlook
This section provides the total Myelodysplastic Syndrome market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Myelodysplastic Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Myelodysplastic Syndrome market size and market size by therapies in Japan is also mentioned.
<h3>Myelodysplastic Syndrome Drugs Uptake</h3>
This section focuses on the rate of uptake of the potential Myelodysplastic Syndrome drugs recently launched in the Myelodysplastic Syndrome market or expected to get launched in the market during the study period 2018 to 2030. The analysis covers Myelodysplastic Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;
Myelodysplastic Syndrome Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Myelodysplastic Syndrome market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
<h3>Myelodysplastic Syndrome Pipeline Development Activities</h3>
The Myelodysplastic Syndrome report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Myelodysplastic Syndrome companies involved in developing targeted therapeutics.
<h3>Pipeline Development Activities</h3>
The Myelodysplastic Syndrome report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Myelodysplastic Syndrome emerging therapies.
<h2>Competitive Intelligence Analysis</h2>
We perform competitive and market Intelligence analysis of the Myelodysplastic Syndrome market by using various competitive intelligence tools that include&ndash;SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of MDS, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.</li>
<li>Comprehensive insight has been provided into the MDS epidemiology and treatment.</li>
<li>Additionally, an all-inclusive account of both the current and emerging therapies for MDS are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.</li>
<li>A detailed review of the MDS; historical and forecasted is included in the report, covering the 7MM drug outreach.</li>
<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM MDS Injury market.</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>In the coming years, the MDS market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.</li>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence MDS R&amp;D. The therapies under development are focused on novel approaches to treat/improve the disease condition.</li>
<li>Delvelnsight has analysed incident population of MDS in the 7MM which suggests that the cases of MDS will increase during the forecast period of 2021&ndash;2030.</li>
<li>Age-specific data of MDS suggests that incidence of MDS in the US, was highest in the age group of 80+ years, followed by 70&ndash;79 years and 60&ndash;69 years.</li>
<li>The scope of the report also encompasses another major segment, i.e., mutation-specific incidence MDS, wherein the number of patients suffering from mutations of&nbsp; SF3B1, SRSF2, U2AF1, DNMT3A, RUNX1 TP53, TET2, ASXL1, ZRSR2, and IDH2 were calculated.</li>
<li>There are sub- types of MDS considered in this report include MDS can be broadly categorized into the following subtypes: RAEB/MDS-EB, del(5q) MDS, MDS-RS/RARS, MDS-MLD/RCMD, MDS-SLD/RCUD, and MDS-U.</li>
<li>Currently available therapies include growth factor support, lenalidomide, Reblozyl, HMAs, intensive chemotherapy, and alloSCT along with the drugs approved in 2020, luspatercept and the oral HMA ASTX727.</li>
<li>Expected Launch of potential therapies by key players like , FibroGen (roxadustat), AbbVie (Venclexta &plusmn; azacitidine), Novartis (sabatolimab), Syros Pharmaceuticals (SY-1425 + azacitidine), Gilead Sciences (magrolimab &plusmn; azacitidine), Geron Corporation (imetelstat), Takeda (pevonedistat &plusmn; azacitidine), Pfizer (glasdegib + azacitidine), Aprea Therapeutics (eprenetapopt), Jazz Pharmaceuticals (CPX-351), Karyopharm Therapeutics (eltanexor), BerGenBio (bemcentinib), Bristol Myers Squibb (enasidenib), Sanofi (fludarabine + busulfan &plusmn; clofarabine), Medac (treosulfan &plusmn; fludarabine) and others may increase the market size in the coming years, assisted by an increase in the incident population of Myelodysplastic Syndrome (MDS). It is expected that these therapies will help thrive the market of Myelodysplastic Syndrome (MDS) post-launch, in the United States. Furthermore, these novel therapies will mark there entry in the EU5 countries and Japan in subsequent years.</li>
</ul>
<h2>Analyst Comments</h2>
<ul>
<li>Companies like Bristol Myers Squibb, Aprea Therapeutics, Geron Corporation, and others are developing therapies targeting certain mutations like TP53, IDH2, RARA, etc.&nbsp; This will provide more precise treatment for MDS patients not responding or having poor outcomes toward the current standard of treatment.</li>
<li>Various therapies for second-line settings are also being developed, which will provide more treatment options for the patients, as there are currently no approved second-line treatments for MDS.</li>
<li>Therapies like imetelstat, treosulfan, and SY-1425 + azacitidine, are expected to enter the market sooner than the other therapies, as their respective companies are planning to file for NDA soon.</li>
</ul>
<h2>Myelodysplastic Syndrome Report Insights</h2>
<ul>
<li>Patient Population</li>
<li>Therapeutic Approaches</li>
<li>Myelodysplastic Syndrome Pipeline Analysis</li>
<li>Myelodysplastic Syndrome Market Size and Trends</li>
<li>Market Opportunities</li>
<li>Impact of upcoming Therapies</li>
</ul>
<h2>Myelodysplastic Syndrome Report Key Strengths</h2>
<ul>
<li>Ten Years Forecast</li>
<li>7MM Coverage</li>
<li>Myelodysplastic Syndrome Epidemiology Segmentation</li>
<li>Key Cross Competition</li>
<li>Highly Analyzed Market</li>
<li>Drugs Uptake</li>
</ul>
<h2>Myelodysplastic Syndrome Report Assessment</h2>
<ul>
<li>Current Treatment Practices</li>
<li>Unmet Needs</li>
<li>Pipeline Product Profiles</li>
<li>Market Attractiveness</li>
<li>Market Drivers and Barriers</li>
</ul>
<h2>Key Questions</h2>
Market Insights:
<ul>
<li>What was the Myelodysplastic Syndrome market share (%) distribution in 2018 and how it would look like in 2030?</li>
<li>What would be the Myelodysplastic Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2021&ndash;2030)?</li>
<li>What are the key findings pertaining to the market across the 7MM</li>
<li>Which country will have the largest Myelodysplastic Syndrome market size during the forecast period (2021&ndash;2030)?</li>
<li>At what CAGR, the Myelodysplastic Syndrome market is expected to grow in the 7MM during the forecast period (2021&ndash;2030)?</li>
<li>What would be the Myelodysplastic Syndrome market outlook across the 7MM during the forecast period (2021&ndash;2030)?</li>
<li>What would be the Myelodysplastic Syndrome market growth till 2030 and what will be the resultant market size in the year 2030?</li>
<li>How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?</li>
</ul>
&nbsp;
Epidemiology Insights:
<ul>
<li>What is the disease risk, burden and unmet needs of Myelodysplastic Syndrome?</li>
<li>What is the historical Myelodysplastic Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?</li>
<li>What would be the forecasted patient pool of Myelodysplastic Syndrome at the 7MM?</li>
<li>What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Myelodysplastic Syndrome?</li>
<li>Out of the above-mentioned countries, which country would have the highest incident population of Myelodysplastic Syndrome during the forecast period (2021&ndash;2030)?</li>
<li>At what CAGR the population is expected to grow across the 7MM during the forecast period (2021&ndash;2030)?</li>
</ul>
&nbsp;
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
<ul>
<li>What are the current options for the treatment of Myelodysplastic Syndrome along with the approved therapy?</li>
<li>What are the current treatment guidelines for the treatment of Myelodysplastic Syndrome in the US, Europe and Japan?</li>
<li>What are the Myelodysplastic Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?</li>
<li>How many companies are developing therapies for the treatment of Myelodysplastic Syndrome?</li>
<li>How many therapies are developed by each company for the treatment of Myelodysplastic Syndrome?</li>
<li>How many emerging therapies are in the mid-stage and late stage of development for the treatment of Myelodysplastic Syndrome?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myelodysplastic Syndrome therapies?</li>
<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Myelodysplastic Syndrome and their status?</li>
<li>What are the key designations that have been granted for the emerging therapies for Myelodysplastic Syndrome?</li>
<li>What are the 7MM historical and forecasted market of Myelodysplastic Syndrome?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>The report will help in developing business strategies by understanding trends shaping and driving Myelodysplastic Syndrome.</li>
<li>To understand the future market competition in the Myelodysplastic Syndrome market and an Insightful review of the key market drivers and barriers.</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for Myelodysplastic Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), And Japan.</li>
<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for the Myelodysplastic Syndrome market.</li>
<li>To understand the future market competition in the Myelodysplastic Syndrome market.</li>
</ul>

1. Key Insights
2. Executive Summary of Myelodysplastic Syndrome
3. Competitive Intelligence Analysis for Myelodysplastic Syndrome
4. Myelodysplastic Syndrome: Market Overview at a Glance
4.1. Myelodysplastic Syndrome Total Market Share (%) Distribution in 2018
4.2. Myelodysplastic Syndrome Total Market Share (%) Distribution in 2030
5. Myelodysplastic Syndrome: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Myelodysplastic Syndrome Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Myelodysplastic Syndrome Epidemiology Scenario in the 7MM (2018-2030)
7.4. United States Epidemiology
7.4.1. Myelodysplastic Syndrome Epidemiology Scenario in the United States (2018-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Myelodysplastic Syndrome Epidemiology Scenario in Germany (2018-2030)
7.5.2. France Epidemiology
7.5.2.1. Myelodysplastic Syndrome Epidemiology Scenario in France (2018-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Myelodysplastic Syndrome Epidemiology Scenario in Italy (2018-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Myelodysplastic Syndrome Epidemiology Scenario in Spain (2018-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Myelodysplastic Syndrome Epidemiology Scenario in the United Kingdom (2018-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Myelodysplastic Syndrome Epidemiology Scenario in Japan (2018-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Myelodysplastic Syndrome Treatment and Management
8.2. Myelodysplastic Syndrome Treatment Algorithm
9. Myelodysplastic Syndrome&nbsp;Unmet Needs
10. Key Endpoints of Myelodysplastic Syndrome Treatment
11. Myelodysplastic Syndrome&nbsp;Marketed Products
11.1. List of Myelodysplastic Syndrome Marketed Drugs in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Myelodysplastic Syndrome&nbsp;Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Myelodysplastic Syndrome: Seven Major Market Analysis
13.1. Key Findings
13.2. Myelodysplastic Syndrome Market Size in 7MM
13.3. Myelodysplastic Syndrome Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Myelodysplastic Syndrome Total Market Size in the United States
15.1.2. Myelodysplastic Syndrome Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Myelodysplastic Syndrome Total Market Size in Germany
15.3.2. Myelodysplastic Syndrome Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Myelodysplastic Syndrome Total Market Size in France
15.4.2. Myelodysplastic Syndrome Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Myelodysplastic Syndrome Total Market Size in Italy
15.5.2. Myelodysplastic Syndrome Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Myelodysplastic Syndrome Total Market Size in Spain
15.6.2. Myelodysplastic Syndrome Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Myelodysplastic Syndrome Total Market Size in the United Kingdom
15.7.2. Myelodysplastic Syndrome Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Myelodysplastic Syndrome Total Market Size in Japan
15.8.3. Myelodysplastic Syndrome Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Myelodysplastic Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.

Myelodysplastic Syndrome- Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides  the detailed overview of the disease and in depth understanding..